Min Fang
Direktor/Vorstandsmitglied bei InSilico Medicine, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Aleksandrs Zhavoronkov | M | - |
InSilico Medicine, Inc.
 InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.
Insilico Medicine Cayman TopCo
 Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 10 Jahre |
| Yiwen Zhu | M | 60 | 15 Jahre | |
| Feng Ren | M | 49 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 3 Jahre |
| Ren Feng | M | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | - |
| Aleksandr Aliper | M | 34 |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 10 Jahre |
| Steven Kenneth Galson | M | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | - |
| Jun Wang | F | 37 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 4 Jahre |
| Jing Song Wang | M | 60 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 1 Jahre |
| Roman Kyrychynskyi | M | 48 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 1 Jahre |
| Denitsa Milanova | M | 39 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 1 Jahre |
| Kan Chen | M | 42 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | 3 Jahre |
| Paul Stuart Auerbach | M | 72 |
Stanford University
| 19 Jahre |
| Evelyne Bischof | M | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | 5 Jahre |
| Sujata Rao | M | 64 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 2 Jahre |
| Jennifer Cochran | M | 52 |
Stanford University
| 19 Jahre |
| Kan Chen | - | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | - |
| Fred M. Gibbons | M | 75 |
Stanford University
| 18 Jahre |
| Garri Zmudze | M | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | 8 Jahre |
| Ming Zi Chen | M | 54 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 3 Jahre |
| Stefan Heller | M | 58 |
Stanford University
| 19 Jahre |
| Kwan Wai Leung | F | 43 |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | 1 Jahre |
| Frank M. Longo | M | - |
Stanford University
| 18 Jahre |
| Kwok Yin Lau | M | 39 | 3 Jahre | |
| Evgeny Izumchenko | M | - |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | 9 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Styrmir Sigurjonsson | M | 50 |
Stanford University
| 7 Jahre |
| Aparna Sinha | M | - |
Stanford University
| - |
| Hesaam Esfandyarpour | M | - |
Stanford University
| 5 Jahre |
| Helmy Eltoukhy | M | 45 |
Stanford University
| 9 Jahre |
| Ben Daniel | M | - |
Stanford University
| 1 Jahre |
| Chase Beeler | M | - |
Stanford University
| 5 Jahre |
| Zavain Dar | M | 35 |
Stanford University
| 6 Jahre |
| Jung-il Choi | M | - |
Stanford University
| 6 Jahre |
| Hugh Browne | M | - |
Stanford University
| 2 Jahre |
| Iveshu Bhatia | M | - |
Stanford University
| 1 Jahre |
| Geoffrey Woo | M | - |
Stanford University
| 4 Jahre |
| Joel Dudley | M | - |
Stanford University
| 4 Jahre |
| Adam Klotz | M | - |
Stanford University
| 10 Jahre |
| Etosha Cave | M | - |
Stanford University
| 8 Jahre |
| Kathy Hannun | F | - |
Stanford University
| 10 Jahre |
| Eric Bahn | M | - |
Stanford University
| 5 Jahre |
| Elaine Zelby | F | - |
Stanford University
| 5 Jahre |
| Mada Seghete | F | - |
Stanford University
| 8 Jahre |
| Greg Kress | M | - |
Stanford University
| 5 Jahre |
| Haomiao Huang | M | - |
Stanford University
| 7 Jahre |
| Neel Murthy | M | - |
Stanford University
| 6 Jahre |
| Joseph Lau | M | - |
Stanford University
| - |
| Wesley Lim | M | - |
Stanford University
| 4 Jahre |
| Brain Banwoong Koo | M | - |
Stanford University
| 2 Jahre |
| Nabeel Hasnain | M | - |
Stanford University
| 4 Jahre |
| Erin Yang | F | - |
Stanford University
| 5 Jahre |
| Forrest White | M | - |
Stanford University
| 5 Jahre |
| Zheng Su | F | - |
Stanford University
| 4 Jahre |
| Andreas Eckner | M | - |
Stanford University
| 4 Jahre |
| John Melas-Kyriazi | M | - |
Stanford University
| 4 Jahre |
| Charles H. House | M | 83 |
Stanford University
| - |
| Samir Siddhanti | M | - |
Stanford University
| 5 Jahre |
| Alex W. Bergman | M | - |
Stanford University
| 2 Jahre |
| Emily Melton | F | - |
Stanford University
| 10 Jahre |
| Manu Kumar | M | - |
Stanford University
| 5 Jahre |
| Elvina Mintarno | F | - |
Stanford University
| 4 Jahre |
| Ali Jamal | M | - |
Stanford University
| 5 Jahre |
| Andrew Gustin | M | - |
Stanford University
| 9 Jahre |
| Elizabeth Weil | F | - |
Stanford University
| 6 Jahre |
| Gee-Liek Yeo | M | - |
Stanford University
| 6 Jahre |
| Rapp Alyssa | F | 45 |
Stanford University
| 2 Jahre |
| Curtis Spencer | M | - |
Stanford University
| - |
| Manu Lakkur | M | - |
Stanford University
| 5 Jahre |
| Dmitry Pushkarev | M | - |
Stanford University
| 5 Jahre |
| Elizabeth Xie | M | - |
Stanford University
| 6 Jahre |
| Alex Gurevich | M | - |
Stanford University
| 5 Jahre |
| Mike Rothenberg | M | - |
Stanford University
| 5 Jahre |
| Stephen D. Klein | M | - |
Stanford University
| 5 Jahre |
| John Komkov | M | - |
Stanford University
| 10 Jahre |
| Satyan Gajwani | M | 39 |
Stanford University
| 4 Jahre |
| Karen Martell | F | - |
Stanford University
| 4 Jahre |
| Kunal Ghosh | M | - |
Stanford University
| 5 Jahre |
| Nick Noone | M | - |
Stanford University
| 4 Jahre |
| Lyndsay Erickson | F | - |
Stanford University
| 5 Jahre |
| Michael Paulus | M | - |
Stanford University
| 5 Jahre |
| James P. McGillicuddy | M | - |
Stanford University
| 5 Jahre |
| Guillaume Horel | M | - |
Stanford University
| 4 Jahre |
| Jason Min | M | - |
Stanford University
| 6 Jahre |
| Steve Abraham | M | - |
Stanford University
| 5 Jahre |
| David Liu | M | - |
Stanford University
| 4 Jahre |
| Soo Huan Xi | M | - |
Stanford University
| 1 Jahre |
| Vivek Patel | M | 45 |
Stanford University
| 1 Jahre |
| Kent Kristin | F | - |
Stanford University
| 4 Jahre |
| Li Lu | M | - |
Stanford University
| 7 Jahre |
| Austin Yount | M | - |
Stanford University
| 3 Jahre |
| Steve Levin | M | - |
Stanford University
| 2 Jahre |
| Scott Hofmeister | M | - |
Stanford University
| 4 Jahre |
| Sara Thomas Deshpande | F | - |
Stanford University
| 2 Jahre |
| Fiona O'Donnell McCarthy | F | - |
Stanford University
| 4 Jahre |
| Sye Min Chan | F | - |
Stanford University
| 1 Jahre |
| Yun Yau Li | M | 45 |
Stanford University
| 3 Jahre |
| R. Matthew Dunbar | M | 47 |
Stanford University
| 2 Jahre |
| Tamra Johnson | F | - |
Stanford University
| 2 Jahre |
| Yu Chen | M | 43 |
Stanford University
| 1 Jahre |
| Julie H. Park | F | - |
Stanford University
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 89 | 89,90% |
| Hong Kong | 11 | 11,11% |
| China | 2 | 2,02% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
